secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001641172-25-010525
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix reports Q1 loss; plans asset divestment, Cullgen merger close targeted for June
--------------------------------------------------------------------------------

- Q1 2025 revenue $0 vs $5.9M YoY; net loss $1.8M (-$0.50 EPS) vs net income $0.825M in Q1 2024.
- Cash balance $7.7M; expects to fund operations through merger close in June 2025.
- Merger with Cullgen anticipated to close in June 2025; registration declared effective by SEC.
- Company intends to divest assets including PUR3100 (Phase 2-ready acute migraine candidate) and iSPERSE technology.
- R&D expenses decreased to less than $0.1M from $3.5M YoY due to wind-down.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000164117225010525/0001641172-25-010525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000164117225010525/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer